期刊
ONCOTARGET
卷 6, 期 27, 页码 23671-23687出版社
IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.4409
关键词
galectin-3; metastasis; heparin
资金
- Medical Research Council UK [G1000772]
- MRC Industrial Case Studentship
- PhD studentship - MRC [SM-9218, SM-8596]
- PhD studentship - Diamond Light Source UK [SM-9218, SM-8596]
- BBSRC [BB/I004343/1] Funding Source: UKRI
- MRC [G1000772] Funding Source: UKRI
- Medical Research Council [1613926, 1246599, G1000772] Funding Source: researchfish
Concentrations of circulating galectin-3, a metastasis promoter, are greatly increased in cancer patients. Here we show that 2- or 6-de-O-sulfated, N-acetylated heparin derivatives are galectin-3 binding inhibitors. These chemically modified heparin derivatives inhibited galectin-3-ligand binding and abolished galectin-3-mediated cancer cell-endothelial adhesion and angiogenesis. Unlike standard heparin, these modified heparin derivatives and their ultra-low molecular weight sub-fractions had neither anticoagulant activity nor effects on E-, L-or P-selectin binding to their ligands nor detectable cytotoxicity. Intravenous injection of such heparin derivatives ( with cancer cells pre-treated with galectin-3 followed by 3 subcutaneous injections of the derivatives) abolished the circulating galectin-3-mediated increase in lung metastasis of human melanoma and colon cancer cells in nude mice. Structural analysis using nuclear magnetic resonance and synchrotron radiation circular dichroism spectroscopies showed that the modified heparin derivatives bind to the galectin-3 carbohydrate-recognition domain. Thus, these chemically modified, non-anticoagulant, low-sulfated heparin derivatives are potent galectin-3 binding inhibitors with substantial potential as anti-metastasis/ cancer drugs.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据